These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 22584850)

  • 1. Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib.
    Piro E; Kropp M; Cantaffa R; Lamberti AG; Carillio G; Molica S
    Ann Hematol; 2012 Nov; 91(11):1827-8. PubMed ID: 22584850
    [No Abstract]   [Full Text] [Related]  

  • 2. Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases.
    Ziogas DC; Terpos E; Gavriatopoulou M; Migkou M; Fotiou D; Roussou M; Kanellias N; Tatouli I; Eleutherakis-Papaiakovou E; Panagiotidis I; Ntanasis-Stathopoulos I; Kastritis E; Dimopoulos MA
    Leuk Lymphoma; 2018 Apr; 59(4):983-987. PubMed ID: 28782413
    [No Abstract]   [Full Text] [Related]  

  • 3. [Development and clinical application of novel proteasome inhibitors].
    Iida S
    Rinsho Ketsueki; 2012 Apr; 53(4):417-25. PubMed ID: 22687975
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
    Richardson P
    Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of myeloma when high dose therapy is not possible. New drugs--alternatives for elderly patients].
    Mellstedt H; Gimsing P; Waage A
    Lakartidningen; 2011 Oct 19-25; 108(42):2090-4. PubMed ID: 22165535
    [No Abstract]   [Full Text] [Related]  

  • 6. Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
    Bringhen S; Gay F; Donato F; Troia R; Mina R; Palumbo A
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1193-209. PubMed ID: 24905450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperlipidemia in a myeloma patient after bortezomib treatment.
    Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M
    Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499
    [No Abstract]   [Full Text] [Related]  

  • 8. Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation.
    Richardson P
    Oncology (Williston Park); 2006 May; 20(6):633-8. PubMed ID: 16773847
    [No Abstract]   [Full Text] [Related]  

  • 9. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
    Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
    Broyl A; Jongen JL; Sonneveld P
    Semin Hematol; 2012 Jul; 49(3):249-57. PubMed ID: 22726548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skin lesions induced by bortezomib.
    Pour L; Hajek R; Zdenek A; Krejci M; Krivanova A; Vorlicek J
    Haematologica; 2005 Dec; 90(12 Suppl):ECR44. PubMed ID: 16464759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
    Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
    Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib increases survival of patients with relapsed multiple myeloma.
    Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
    [No Abstract]   [Full Text] [Related]  

  • 14. Dissecting bortezomib: development, application, adverse effects and future direction.
    Cao B; Li J; Mao X
    Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib-induced Sweet syndrome.
    Knoops L; Jacquemain A; Tennstedt D; Theate I; Ferrant A; Van den Neste E
    Br J Haematol; 2005 Oct; 131(2):142. PubMed ID: 16197442
    [No Abstract]   [Full Text] [Related]  

  • 16. Bortezomib for myeloma -- much ado about something.
    Dispenzieri A
    N Engl J Med; 2005 Jun; 352(24):2546-8. PubMed ID: 15958811
    [No Abstract]   [Full Text] [Related]  

  • 17. Bortezomib in multiple myeloma.
    Mateos MV; San Miguel JF
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rectal bleeding and diarrhea caused by bortezomib-induced colitis.
    Nogales Rincón O; Huerta Madrigal A; Merino Rodriguez B; González Asanza C; Cos Arregui E; Menchén Fernández-Pacheco P
    Gastroenterol Hepatol; 2010 Dec; 33(10):753-4. PubMed ID: 20674097
    [No Abstract]   [Full Text] [Related]  

  • 19. Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?
    Pitini V; Arrigo C; Altavilla G; Naro C
    Leuk Res; 2007 Jul; 31(7):1027-8. PubMed ID: 17134751
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase 2 study of bortezomib in relapsed, refractory myeloma.
    Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
    N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.